Variant | DSI v | DPI v | Chr | Position | Consequence | Alleles | Class | AF EXOME | AF GENOME | Disease | Disease Class | Score vda | EI vda | N. PMIDs | First Ref. | Last Ref. | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
1.000 | 9 | 136523177 | stop gained | G/A | snv |
|
0.700 | 1.000 | 1 | 2018 | 2018 | ||||||||||
|
1.000 | 0.040 | 9 | 136506782 | missense variant | G/A | snv | 3.7E-04 | 5.7E-04 |
|
Cardiovascular Diseases | 0.010 | 1.000 | 1 | 2017 | 2017 | ||||||
|
1.000 | 0.040 | 9 | 136505728 | missense variant | G/T | snv | 5.8E-04 | 6.0E-04 |
|
Cardiovascular Diseases | 0.010 | 1.000 | 1 | 2007 | 2007 | ||||||
|
1.000 | 0.080 | 9 | 136510659 | missense variant | G/A | snv | 1.7E-03 | 2.2E-03 |
|
Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Digestive System Diseases | 0.010 | 1.000 | 1 | 2019 | 2019 | ||||||
|
0.827 | 0.120 | 9 | 136495945 | 3 prime UTR variant | C/T | snv | 0.62 |
|
Neoplasms; Skin and Connective Tissue Diseases | 0.010 | 1.000 | 1 | 2014 | 2014 | |||||||
|
0.827 | 0.120 | 9 | 136495945 | 3 prime UTR variant | C/T | snv | 0.62 |
|
Neoplasms | 0.010 | 1.000 | 1 | 2014 | 2014 | |||||||
|
0.827 | 0.120 | 9 | 136495945 | 3 prime UTR variant | C/T | snv | 0.62 |
|
Neoplasms; Skin and Connective Tissue Diseases | 0.010 | 1.000 | 1 | 2014 | 2014 | |||||||
|
0.827 | 0.120 | 9 | 136495945 | 3 prime UTR variant | C/T | snv | 0.62 |
|
Neoplasms; Skin and Connective Tissue Diseases | 0.010 | 1.000 | 1 | 2014 | 2014 | |||||||
|
0.827 | 0.120 | 9 | 136495945 | 3 prime UTR variant | C/T | snv | 0.62 |
|
Female Urogenital Diseases and Pregnancy Complications; Male Urogenital Diseases | 0.010 | 1.000 | 1 | 2018 | 2018 | |||||||
|
0.827 | 0.120 | 9 | 136495945 | 3 prime UTR variant | C/T | snv | 0.62 |
|
Cardiovascular Diseases | 0.010 | 1.000 | 1 | 2014 | 2014 | |||||||
|
9 | 136498710 | intron variant | G/A | snv | 0.55 |
|
0.700 | 1.000 | 1 | 2017 | 2017 | ||||||||||
|
9 | 136498710 | intron variant | G/A | snv | 0.55 |
|
0.700 | 1.000 | 1 | 2017 | 2017 | ||||||||||
|
0.882 | 0.080 | 9 | 136501956 | intron variant | A/G | snv | 0.59 | 0.62 |
|
Neoplasms; Respiratory Tract Diseases | 0.010 | < 0.001 | 1 | 2017 | 2017 | ||||||
|
0.882 | 0.080 | 9 | 136501956 | intron variant | A/G | snv | 0.59 | 0.62 |
|
Neoplasms; Respiratory Tract Diseases | 0.010 | < 0.001 | 1 | 2017 | 2017 | ||||||
|
0.882 | 0.080 | 9 | 136501956 | intron variant | A/G | snv | 0.59 | 0.62 |
|
Neoplasms; Respiratory Tract Diseases | 0.010 | < 0.001 | 1 | 2017 | 2017 | ||||||
|
9 | 136507052 | intron variant | G/A | snv | 0.57 |
|
0.700 | 1.000 | 1 | 2019 | 2019 | ||||||||||
|
0.851 | 0.080 | 9 | 136509318 | intron variant | G/A | snv | 0.13 |
|
Neoplasms; Respiratory Tract Diseases | 0.010 | 1.000 | 1 | 2017 | 2017 | |||||||
|
0.851 | 0.080 | 9 | 136509318 | intron variant | G/A | snv | 0.13 |
|
Neoplasms; Respiratory Tract Diseases | 0.010 | < 0.001 | 1 | 2017 | 2017 | |||||||
|
0.851 | 0.080 | 9 | 136509318 | intron variant | G/A | snv | 0.13 |
|
Female Urogenital Diseases and Pregnancy Complications; Male Urogenital Diseases | 0.010 | 1.000 | 1 | 2018 | 2018 | |||||||
|
0.851 | 0.080 | 9 | 136509318 | intron variant | G/A | snv | 0.13 |
|
Neoplasms; Respiratory Tract Diseases | 0.010 | < 0.001 | 1 | 2017 | 2017 | |||||||
|
0.851 | 0.080 | 9 | 136509318 | intron variant | G/A | snv | 0.13 |
|
Neoplasms; Respiratory Tract Diseases | 0.010 | < 0.001 | 1 | 2017 | 2017 | |||||||
|
0.882 | 0.080 | 9 | 136520387 | intron variant | G/A;C | snv |
|
Neoplasms; Respiratory Tract Diseases | 0.010 | < 0.001 | 1 | 2017 | 2017 | ||||||||
|
0.882 | 0.080 | 9 | 136520387 | intron variant | G/A;C | snv |
|
Neoplasms; Respiratory Tract Diseases | 0.010 | < 0.001 | 1 | 2017 | 2017 | ||||||||
|
0.882 | 0.080 | 9 | 136520387 | intron variant | G/A;C | snv |
|
Neoplasms; Respiratory Tract Diseases | 0.010 | < 0.001 | 1 | 2017 | 2017 | ||||||||
|
0.827 | 0.120 | 9 | 136494980 | 3 prime UTR variant | C/T | snv | 3.0E-02 |
|
Musculoskeletal Diseases | 0.700 | 1.000 | 1 | 2016 | 2016 |